Skip to main content

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Final decision follows multiple previous court rulings in favor of Natera and upholds invalidation of CareDx patents

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.’s (NASDAQ: CDNA) petition for certiorari concerning a patent infringement lawsuit brought by CareDx against Natera. This decision confirms the invalidity of the patents asserted against Natera and follows three previous rulings on the matter:

  1. A September 2021 decision by the United States District Court for the District of Delaware, affirming that all three CareDx patents asserted against Natera were invalid for claiming patent-ineligible subject matter.
  2. A June 2022 decision by the United States Court of Appeals for the Federal Circuit, affirming the Delaware Court’s decision.
  3. A December 2022 denial of rehearing by the United States Court of Appeals for the Federal Circuit.

This final decision by the Supreme Court rejects the request by CareDx to litigate this matter once again and effectively terminates any existing claims brought by CareDx against Natera concerning these patents.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights, and our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and


Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350,

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc.,

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.